Cancer News and Research

Latest Cancer News and Research

Aeterna Zentaris selects optimized Erk inhibitor molecule for further development

Aeterna Zentaris Inc. today announced it has selected an optimized Erk inhibitor molecule for development, thus achieving another important milestone in the development of a new class of potential cancer therapies.

29 Jul 2015

World Health Organization recognizes unique pharmacological nature of Can-Fite's CF101, grants new generic name

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today announced that the World Health Organization's International Nonproprietary Name group has accepted the proposed generic name "piclidenoson" for its lead drug candidate, CF101.

29 Jul 2015

PDL BioPharma signs revenue interest assignment agreement with ARIAD Pharmaceuticals

PDL BioPharma, Inc. today announced that it has entered into a revenue interest assignment agreement (the "Agreement") in which it has agreed to provide ARIAD Pharmaceuticals, Inc. with up to $200 million in revenue interest financing in exchange for royalties on the net revenues of Iclusig (ponatinib).

29 Jul 2015

Study reveals that firms 'underinvest' in long-term research to develop cancer-fighting drugs

Pharmaceutical firms "underinvest" in long-term research to develop new cancer-fighting drugs due to the greater time and cost required to conduct such research, according to a newly published study co-authored by MIT economists.

29 Jul 2015

Radiation from solar events too weak to cause birth defects down on Earth's surface

Studies find airplane crews at high altitude are exposed to potentially harmful levels of radiation from cosmic rays.

29 Jul 2015

New tool combines drugs to target kinase dependency in cancer

Targeted therapies attack a cancer's genetic sensitivities. However, it can be difficult to discover the genetics driving a patient's cancer, and the effects of drugs designed to target a genetic abnormality often go beyond their intended target alone. The result is threefold: sometimes a drug is prescribed to treat a target that proves to be irrelevant to the disease, sometimes an existing drug could be used to treat a cancer for which there is no approved targeted therapy, and sometimes a combination of targeted treatments could be used to simultaneously silence more than one genetic cause of a patient's cancer.

29 Jul 2015

New consortium aims to develop precision medicines for globally devastating diseases

An innovative new Consortium will act as a ‘match-making’ service between pharmaceutical companies and researchers in Cambridge with the aim of developing and studying precision medicines for some of the most globally devastating diseases.

29 Jul 2015

Moffitt researchers analyze participation rate of patients in pharmacogenomic trials

Cancer therapy has evolved from a "one-size-fits-all" type of treatment plan to a personalized approach based on a patient's type of cancer, the protein and genetic markers found in their tumors and their response to therapy. Important aspects of the personalized approach are pharmacogenomic studies that analyze associations between genetic variations and patient drug responses.

29 Jul 2015

New polymer gel could help create swallowable devices for ultra-long drug delivery

Medical devices designed to reside in the stomach have a variety of applications, including prolonged drug delivery, electronic monitoring, and weight-loss intervention. However, these devices, often created with nondegradable elastic polymers, bear an inherent risk of intestinal obstruction as a result of accidental fracture or migration. As such, they are usually designed to remain in the stomach for a limited time.

29 Jul 2015

Recycling older electronic devices increases exposure to lead, creates health concern

The disposal and recycling of electronic devices has increased exposure to lead and other toxicants and created "an emerging health concern," according to a pediatrician who directs the Environmental Health and Lead Clinic at Cincinnati Children's Hospital Medical Center.

29 Jul 2015

Moffitt researchers find cancer healthcare disparities in LGBTQ community

The Lesbian, Gay, Bisexual, Transgender/Transsexual, Queer/Questioning (LGBTQ) community is a growing and medically-underserved minority population in the United States, with 3 to 12 percent of the population estimated to identify as LGBTQ.

29 Jul 2015

Study elucidates on global prevalence of chronic hepatitis B infections

Hepatitis B infections are among the most common infectious diseases worldwide. The disease can become chronic, and is one of the most important causes of severe diseases such as liver cancer. In the scope of an international study funded by the World Health Organization, scientists from the Helmholtz Centre for Infection Research in Braunschweig determined how often the chronic infection occurs in different countries and how many people of the general population are affected. They noted strong differences between different countries.

29 Jul 2015

Researchers establish safety, dosing of new drug for treating blood cancers

Researchers at University of California, San Diego School of Medicine have established the safety and dosing of a new drug for treating blood cancers. The findings are published online July 27 in The Lancet Haematology.

29 Jul 2015

Researchers at Sydney’s Centenary Institute fight against hepatitis infection

Today is World Hepatitis Day. 400 million people around the world are currently living with hepatitis B or C. Each year, we see around 1.4 million people die from viral hepatitis. Researchers at Sydney’s Centenary Institute are working hard to change this.

28 Jul 2015

Research brief provides clinical validation of LOXO-101 Phase 1 trial for treatment of TRK fusion cancer

The University of Colorado Cancer Center and Loxo Oncology, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of targeted cancer therapies, today announced the publication of a research brief in the online edition of the journal Cancer Discovery, describing the first patient with a tropomyosin receptor kinase fusion cancer enrolled in the Phase 1 dose escalation trial of LOXO-101, the only selective TRK inhibitor in clinical development.

28 Jul 2015

German life sciences entrepreneurs granted option to develop Aeterna Zentaris’ oral allogenic tumor vaccine technology

Aeterna Zentaris Inc. today announced that it has granted to German life sciences entrepreneurs with a proven track-record of funding the development and commercialization of biotechnology, an option to license the Company's live recombinant oral allogenic tumor vaccine technology, including AEZS-120, the most advanced product candidate for prostate cancer which is ready to enter a Phase 1 clinical trial.

28 Jul 2015

VolitionRx selects Global Specimen Solutions to support U.S. market entry of NuQ colorectal cancer tests

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that it has engaged the services of a specialty specimen management clinical research organization, Global Specimen Solutions, Inc., to support initial U.S. market entry of its NuQ colorectal cancer tests.

28 Jul 2015

Europe has increasing prevalence of fungal resistance, warns ESCMID

The European Society of Clinical Microbiology and Infectious Disease – an organization that explores the risks and best practices in infectious disease – is imploring global healthcare professionals and bodies to take a more active role in the growing problem of fungal resistance.

28 Jul 2015

Champions Oncology's revenue increases 32% to $3.2 million in fourth quarter 2015

Champions Oncology, Inc., engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the year ended April 30, 2015.

28 Jul 2015

ESSA Pharma receives final approval to start trading on Toronto Stock Exchange

ESSA Pharma Inc. is pleased to announce that it has received final approval for its common shares to be listed and commence trading on the Toronto Stock Exchange.

28 Jul 2015

Cancer News and Research

Latest Cancer News and Research

Aeterna Zentaris selects optimized Erk inhibitor molecule for further development

World Health Organization recognizes unique pharmacological nature of Can-Fite's CF101, grants new generic name

PDL BioPharma signs revenue interest assignment agreement with ARIAD Pharmaceuticals

Study reveals that firms 'underinvest' in long-term research to develop cancer-fighting drugs

Radiation from solar events too weak to cause birth defects down on Earth's surface

New tool combines drugs to target kinase dependency in cancer

New consortium aims to develop precision medicines for globally devastating diseases

Moffitt researchers analyze participation rate of patients in pharmacogenomic trials

New polymer gel could help create swallowable devices for ultra-long drug delivery

Recycling older electronic devices increases exposure to lead, creates health concern

Moffitt researchers find cancer healthcare disparities in LGBTQ community

Study elucidates on global prevalence of chronic hepatitis B infections

Researchers establish safety, dosing of new drug for treating blood cancers

Researchers at Sydney’s Centenary Institute fight against hepatitis infection

Research brief provides clinical validation of LOXO-101 Phase 1 trial for treatment of TRK fusion cancer

German life sciences entrepreneurs granted option to develop Aeterna Zentaris’ oral allogenic tumor vaccine technology

VolitionRx selects Global Specimen Solutions to support U.S. market entry of NuQ colorectal cancer tests

Europe has increasing prevalence of fungal resistance, warns ESCMID

Champions Oncology's revenue increases 32% to $3.2 million in fourth quarter 2015

ESSA Pharma receives final approval to start trading on Toronto Stock Exchange

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Building quality into drug development for safer, faster medicines

How Pulp Fixin Is Turning Paper into High-Performance Sustainable Labware

A new method to measure intracellular water in biological systems

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Building quality into drug development for safer, faster medicines

How Pulp Fixin Is Turning Paper into High-Performance Sustainable Labware

A new method to measure intracellular water in biological systems

Newsletters you may be interested in